Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SMΝΔ7 mice show breathing and airflow defects with significant pathology of respiratory and oral tract tissues.

Frontiers in cellular neuroscience·2026
Same author

The FVB-nmd SMARD1 mouse presents with early respiratory deficits and pathology that significantly impact lifespan.

Human molecular genetics·2026
Same author

Targeting SARS-CoV-2 main protease (3CL<sup>pro</sup>) with Paeonia-derived phytochemicals.

In silico pharmacology·2026
Same author

SETD5 dysfunction in human astrocytes drives IL-6-mediated neuronal impairments via the JAK/STAT signaling pathway.

bioRxiv : the preprint server for biology·2026
Same author

Structure-Activity Relationship Studies toward the Optimization of First-In-Class Selective Small Molecule Agonists of the GPCR Relaxin/Insulin-like Family Peptide Receptor 2.

Journal of medicinal chemistry·2026
Same author

The Race to Salvage Glucocerebrosidase: Understanding Small-Molecule Therapies for GBA1-Associated Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society·2025

Related Experiment Video

Updated: Sep 27, 2025

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
11:03

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy

Published on: December 8, 2021

3.9K

A combinatorial approach increases SMN level in SMA model mice.

Samantha A Dumas1, Eric Villalón2,3, Elizabeth M Bergman1

  • 1Department of Anatomy, Physiology, and Genetics, Uniformed Services University of the Health Sciences, F. Edward Herbert School of Medicine, Bethesda, MD 20814, USA.

Human Molecular Genetics
|April 14, 2022
PubMed
Summary

This study shows combining two treatments synergistically boosts survival motor neuron (SMN) protein levels, improving spinal muscular atrophy (SMA) mouse models. This combinatorial therapy enhances motor function and survival in SMA mice.

More Related Videos

Low-Cost Gait Analysis for Behavioral Phenotyping of Mouse Models of Neuromuscular Disease
05:53

Low-Cost Gait Analysis for Behavioral Phenotyping of Mouse Models of Neuromuscular Disease

Published on: July 18, 2019

16.9K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.8K

Related Experiment Videos

Last Updated: Sep 27, 2025

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
11:03

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy

Published on: December 8, 2021

3.9K
Low-Cost Gait Analysis for Behavioral Phenotyping of Mouse Models of Neuromuscular Disease
05:53

Low-Cost Gait Analysis for Behavioral Phenotyping of Mouse Models of Neuromuscular Disease

Published on: July 18, 2019

16.9K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.8K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Spinal muscular atrophy (SMA) is a neurodegenerative disease linked to reduced survival motor neuron (SMN) protein expression.
  • Current therapies improve SMA patient outcomes but are not cures, with variable SMN protein induction observed.
  • Combinatorial strategies show promise in improving SMA outcomes in preclinical models.

Purpose of the Study:

  • To investigate the synergistic effects of inhibiting SMN protein degradation and correcting SMN splicing defects in SMA.
  • To determine if combining ML372 and an SMN-modifying antisense oligonucleotide (ASO) enhances SMN production and ameliorates SMA pathology.
  • To evaluate the impact of this combinatorial approach on motor function and survival in SMA model mice.

Main Methods:

  • Co-administration of ML372 (SMN ubiquitination inhibitor) and an SMN-modifying ASO in SMA cells and model mice.
  • Assessment of SMN protein levels, spinal cord, neuromuscular junction, and muscle pathology.
  • Evaluation of motor function and survival rates in treated SMA mice.

Main Results:

  • Combined treatment with ML372 and ASO significantly increased SMN production in SMA cells and model mice.
  • Observed improvements in spinal cord, neuromuscular junction, and muscle pathology in the combination group.
  • The combinatorial approach led to enhanced motor function and extended survival in SMA mice compared to individual treatments.

Conclusions:

  • Combining SMN protein degradation inhibition with splicing correction offers a synergistic therapeutic strategy for SMA.
  • This combinatorial approach effectively increases SMN levels and improves the pathophysiology of SMA model mice.
  • Targeting multiple pathways represents a promising strategy for enhancing therapeutic efficacy in SMA.